Dressler, Dirk
Bhidayasiri, Roongroj
Bohlega, Saeed
Chana, Pedro
Chien, Hsin Fen
Chung, Tae Mo
Colosimo, Carlo
Ebke, Markus
Fedoroff, Klemens
Frank, Bernd
Kaji, Ryuji
Kanovsky, Petr
Koçer, Serdar
Micheli, Federico
Orlova, Olga
Paus, Sebastian
Pirtosek, Zvezdan
Relja, Maja
Rosales, Raymond L.
Sagástegui-Rodríguez, José Alberto
Schoenle, Paul W.
Shahidi, Gholam Ali
Timerbaeva, Sofia
Walter, Uwe
Saberi, Fereshte Adib
Article History
Received: 23 October 2017
Revised: 17 January 2018
Accepted: 18 January 2018
First Online: 8 February 2018
Compliance with ethical standards
:
: Dressler D: DD received honoraria for services provided to Allergan, Ipsen, Merz, Desitin, Syntaxin, Abbvie, Medtronic, St Jude, Boston Scientific, Almirall, Bayer, Sun, Teva, UCB, IAB-Interdisciplinary Working Group for Movement Disorders. He is shareholder of Allergan and holds patents on botulinum toxin and botulinum toxin therapy. Bhidayasiri R: No conflict of interest to report. Stock Ownership in medically related fields: None. Consultancies: Ipsen Pharmaceuticals. Advisory Boards: Britannia Pharmaceuticals. Honoraria to speak: Novartis, BL Hua, Abbott. Partnerships: None. Grants: Newton Fund UK, Thailand research fund, Ratchadapisek sompot faculty grant and CU-CLUSTER fund of Chulalongkorn University. Intellectual Property Rights: Parkinson’s disease laser cane, Tremor analysis algorithm, Nocturnal monitoring device (NIGHT-Recorder). Expert Testimony: None. Employment: Chulalongkorn University. Royalties: Blackwell-Wiley, Humana Publications. Others: None. Bohlega S: Nothing to declare. Chana P: Nothing to declare. Chien S: Nothing to declare. Chung TM: Honoraria from Ipsen, Allergan and Merz to lecture in Symposium, Training Couses and Advisory Board participation. Participation in clinical research from Ipsen. No research funding and no financial interest in Botulinum Toxin. Colosimo C: Consultancies with Zambon, Sunovion, Ipsen and Bial. Royalties from Cambridge University Press and Oxford University Press. Ebke M: Nothing to declare. Fedoroff K: Nothing to declare. Frank B: Nothing to declare. Kaji R: Nothing to declare. Kanovsky P: Nothing to declare. Kocer S: Nothing to declare. Micheli F: Nothing to declare. Orlova O: OO is scientific consultant for Ipsen, Allergan, Merz and Microgen. PausS: SP received research grants and lecturer fees from Ipsen Pharma and Merz Pharmaceuticals. Member of the Advisory Boards of Ipsen Pharma and Merz Pharmaceuticals. Pirtosek Z: Nothing to declare. Relja M: Northing to declare. Rosales RL: RR received advisory, research and travel grants from Ipsen Pharma and lecture and travel grants from Allergan and Merz Pharma. Sagastequi A: AS received honoraria for lecturing from Allergan and Ipsen. Schoenle PW: Nothing to declare. Shahidi G: Nothing to declare. Timerbaeva S: Nothing to declare. Walter U: UW received speaker honoraria and travel reimbursement from Merz Pharma, Ipsen Pharma, Allergan, Bristol-Myers Squibb, Daiichi Sankyo, Bayer Vital and Pfizer, and a research grant from Merz Pharma. Adib Saberi F: FAS received reimbursement from Abbot, Abbvie, Almirall, Allergan, Bayer, Desitin, Dynamed, Hempel GesundheitsPartner, Ipsen, Johnson & Johnson, Licher, Meda, Medtronic, Merz, Orion, PTZ Nawrath, Sensomotorik & Rehabilitation Hellmuth & Thiel, Sintetica, Sporlastic, Sun, Teva, Tricumed, TRS Med, UCB.
: All human and animal studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.